Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect, HydraSpace, and select toxSYN linker-payloads
Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized therapeutic index
Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin ), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, and Synaffix B.V. (CEO: Peter van de Sande, Synaffix ), a biotechnology company with a clinical-stage platform technology enabling best-in-class antibody-drug conjugates (ADCs), today announced the signing of a license and option agreement.
Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of OFF Episodes in People Living with Parkinson s
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
New Publication Offers Insight into POTELIGEO® (mogamulizumab-kpkc) Treatment Response in Cutaneous T-cell Lymphoma Patients with Varying Levels of Blood Involvement
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Kyowa Kirin Announces EU Approval for the Self-administration of CRYSVITA® ▼ (burosumab) to Treat X-Linked Hypophosphataemia (XLH)
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.